Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease-Reference-Cited by-同舟云学术

Radiation Therapy Followed by Intrathecal Trastuzumab-Pertuzumab for ERBB2-Positive Breast Leptomeningeal Disease

Published:2024-07-01 Issue:7 Volume:10 Page:984
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Ahmed Kamran A.¹,Kumthekar Priya U.²,Pina Yolanda³,Kim Youngchul⁴,Vogelbaum Michael A.³,Han Hyo S.⁵,Forsyth Peter A.³⁶

Affiliation:

1. Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida

2. Department of Neuro-Oncology, Northwestern University, Chicago, Illinois

3. Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida

4. Department of Biostatistics, Moffitt Cancer Center, Tampa, Florida

5. Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida

6. Department of Tumor Biology, Moffitt Cancer Center, Tampa, Florida

Abstract

This nonrandomized controlled trial examines the safety of radiation therapy (RT) followed by intrathecal trastuzumab and pertuzumab for patients with ERBB2-positive breast leptomeningeal disease (LMD).

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2819051/jamaoncology_ahmed_2024_ld_240009_1720732643.18238.pdf

Reference6 articles.

1. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.;Bonneau;Eur J Cancer,2018

2. A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics.;Kumthekar;Neuro Oncol,2023

3. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.;Swain;Lancet Oncol,2020

4. Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease.;Mills;J Neurooncol,2022

5. Keyboard: a novel bayesian toxicity probability interval design for phase I clinical trials.;Yan;Clin Cancer Res,2017